CHICAGO— Overall survival improved by more than two-thirds in patients with metastatic melanoma randomised to have GM-CSF added to their ipilimumab therapy. A phase II study in 245 previously treated patients — comparing the effect of ipilumumab with or without the growth factor — also found side effects were lower among those receiving the combination. At the American Society of Clinical Oncology’s 2013 meeting in Chicago, Sarah Maxwell heard from Dr. Stephen Hodi, Assistant Professor of Medicine at the Dana-Farber Cancer Institute/Harvard Cancer Center, Boston and Dr. Lynn Schuchter Chief of Hematolgy/Oncology at the Abramson Cancer Center, University of Pennsylvania, Philadelphia.
You may also like...
ASCO Audio Journal of Oncology in Advance – June 15th, 2007 – reporting from: ASCO Annual Meeting, Chicago, June 1-5, 2007 16 Jun, 2007 Audio Journal of Oncology 14.1, February 2006 9 Jan, 2006 Bevacizumab: New Standard for Non-Small Cell Lung Cancer? 16 Mar, 2008 Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide 14 Dec, 2007
- Previous story Normal stem cells are not depleted in acute myeloid leukaemia and could be targeted therapeutically
- Next story PD 1 inhibitor nivolumab shows promising activity in metastatic melanoma
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014